William Bradley Acquires 16,129 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director William Bradley purchased 16,129 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were purchased at an average cost of $1.26 per share, for a total transaction of $20,322.54. Following the completion of the acquisition, the director now directly owns 16,129 shares of the company’s stock, valued at $20,322.54. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Fractyl Health Price Performance

GUTS traded down $0.01 during midday trading on Monday, hitting $1.27. 288,389 shares of the company traded hands, compared to its average volume of 297,289. The business has a 50 day simple moving average of $1.66 and a two-hundred day simple moving average of $2.18. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $62.13 million and a price-to-earnings ratio of -0.10. Fractyl Health, Inc. has a 52-week low of $1.16 and a 52-week high of $8.37.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.08). On average, equities analysts forecast that Fractyl Health, Inc. will post -1.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Morgan Stanley lowered their price target on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd.

Hedge Funds Weigh In On Fractyl Health

Institutional investors have recently bought and sold shares of the company. Massachusetts Financial Services Co. MA raised its stake in shares of Fractyl Health by 4.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock valued at $2,646,000 after acquiring an additional 49,289 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Fractyl Health by 56.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock valued at $204,000 after purchasing an additional 29,262 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Fractyl Health by 54.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock worth $53,000 after acquiring an additional 7,397 shares in the last quarter. HighTower Advisors LLC acquired a new position in Fractyl Health during the 3rd quarter worth approximately $38,000. Finally, State Street Corp grew its holdings in Fractyl Health by 129.4% during the 3rd quarter. State Street Corp now owns 113,415 shares of the company’s stock worth $287,000 after acquiring an additional 63,968 shares in the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.